Cell communication and signaling: how to turn bad language into positive one.

Cancer therapy Exosomes Extracellular vesicles Tumor microenvironment microRNAs

Journal

Journal of experimental & clinical cancer research : CR
ISSN: 1756-9966
Titre abrégé: J Exp Clin Cancer Res
Pays: England
ID NLM: 8308647

Informations de publication

Date de publication:
13 Mar 2019
Historique:
received: 11 02 2019
accepted: 28 02 2019
entrez: 15 3 2019
pubmed: 15 3 2019
medline: 25 7 2019
Statut: epublish

Résumé

Cell-to-cell communication has a critical role during tumor development and progression, allowing cancer cell to re-program not only the surrounding tumor microenvironment, but also cells located at distant sites. The crosstalk between neoplastic cells and accessory elements, such as immune and stromal cells, fosters several processes that are necessary for tumor progression and dissemination, such as angiogenesis, immune-escape, epithelial-to-mesenchymal transition, invasion and multi-drug resistance. There are several means by which cells communicate to each other, either by direct cell interactions through membrane receptors and ligands, or by releasing soluble molecules, such as growth factors, cytokines and chemokines. More recently, additional means of cell communication have been identified, such as microRNAs and extracellular vesicles. These two peculiar ways of cell-to-cell interaction were the focus of the 31st Annual Conference of the Italian Association of Cell Cultures (AICC).

Identifiants

pubmed: 30867009
doi: 10.1186/s13046-019-1122-2
pii: 10.1186/s13046-019-1122-2
pmc: PMC6417210
doi:

Types de publication

Clinical Conference Journal Article Lecture

Langues

eng

Pagination

128

Commentaires et corrections

Type : ErratumIn

Références

Proc Natl Acad Sci U S A. 2002 Nov 26;99(24):15524-9
pubmed: 12434020
Nature. 2003 Oct 23;425(6960):836-41
pubmed: 14574412
N Engl J Med. 2005 Oct 27;353(17):1793-801
pubmed: 16251535
Proc Natl Acad Sci U S A. 2006 Apr 25;103(17):6605-10
pubmed: 16636294
Hum Mol Genet. 2006 Apr 15;15 Spec No 1:R17-29
pubmed: 16651366
Breast Cancer Res. 2007;9(3):208
pubmed: 17561992
Blood. 2009 Mar 19;113(12):2673-83
pubmed: 19176319
Proc Natl Acad Sci U S A. 2011 Mar 1;108(9):3713-8
pubmed: 21300873
Int J Cancer. 2012 May 1;130(9):2033-43
pubmed: 21630268
Cancer Res. 2011 Aug 1;71(15):5346-56
pubmed: 21670082
Curr Drug Metab. 2012 Jan;13(1):4-21
pubmed: 22292808
Hepatology. 2012 Sep;56(3):1025-33
pubmed: 22473819
J Exp Clin Cancer Res. 2012 Apr 30;31:38
pubmed: 22546315
J Control Release. 2012 Nov 28;164(1):17-25
pubmed: 23041542
J Immunol. 2013 Mar 15;190(6):2712-9
pubmed: 23418627
Cancer Res. 2013 Jul 1;73(13):3865-76
pubmed: 23658368
Oncoimmunology. 2013 Jun 1;2(6):e24533
pubmed: 23894715
Oncoimmunology. 2013 Oct 1;2(10):e26261
pubmed: 24353911
Adv Colloid Interface Sci. 2014 Mar;205:187-206
pubmed: 24369107
J Clin Oncol. 2014 Mar 10;32(8):768-73
pubmed: 24419137
Cancer Lett. 2014 Jun 28;348(1-2):71-6
pubmed: 24657661
J Control Release. 2014 Jul 10;185:22-36
pubmed: 24747765
J Transl Med. 2014 Aug 21;12:225
pubmed: 25143012
Cell Death Dis. 2014 Dec 04;5:e1559
pubmed: 25476907
Oncotarget. 2015 Apr 10;6(10):7959-69
pubmed: 25797265
BMC Cancer. 2015 Dec 24;15:1009
pubmed: 26704308
Arthritis Res Ther. 2016 Apr 04;18:83
pubmed: 27044395
Oncotarget. 2016 Jun 21;7(25):38707-38717
pubmed: 27231849
Int J Pharm. 2016 Sep 25;511(2):969-82
pubmed: 27498282
Dig Liver Dis. 2016 Dec;48(12):1503-1505
pubmed: 27651344
J Exp Clin Cancer Res. 2016 Sep 29;35(1):156
pubmed: 27686593
Oncotarget. 2016 Nov 22;7(47):76966-76983
pubmed: 27765913
Clin Cancer Res. 2017 Jun 1;23(11):2891-2904
pubmed: 27903673
J Cell Physiol. 2017 Jul;232(7):1826-1834
pubmed: 27925188
EBioMedicine. 2017 Jun;20:182-192
pubmed: 28465156
Genome Biol. 2017 May 24;18(1):98
pubmed: 28535802
Sci Rep. 2017 Jun 9;7(1):3170
pubmed: 28600504
Sci Rep. 2017 Jul 5;7(1):4711
pubmed: 28680152
J Pharm Pharmacol. 1985 Dec;37(12):863-8
pubmed: 2868092
Cancer Lett. 2017 Sep 10;403:318-329
pubmed: 28694142
J Cell Physiol. 2018 Aug;233(8):5937-5948
pubmed: 29244195
J Exp Clin Cancer Res. 2018 Mar 5;37(1):48
pubmed: 29506548
Int J Mol Sci. 2018 Mar 21;19(4):null
pubmed: 29561796
Stem Cells. 2018 Sep;36(9):1329-1340
pubmed: 29770526
J Tissue Eng Regen Med. 2018 Aug;12(8):1835-1842
pubmed: 29770602
Nat Rev Clin Oncol. 2018 Sep;15(9):541-563
pubmed: 29784926
Breast. 2018 Oct;41:42-50
pubmed: 30007267
J Cell Physiol. 2019 Apr;234(4):5044-5055
pubmed: 30187478
Materials (Basel). 2018 Sep 17;11(9):null
pubmed: 30227656
Cancers (Basel). 2018 Oct 05;10(10):null
pubmed: 30301144
Int J Cancer. 2018 Nov 13;:null
pubmed: 30426475
Acta Biomater. 2019 Mar 1;86:1-14
pubmed: 30597259
Clin Cancer Res. 2019 Jan 7;:null
pubmed: 30617131
Mol Ther Nucleic Acids. 2019 Mar 1;14:239-250
pubmed: 30641476

Auteurs

Claudia Chiodoni (C)

Molecular Immunology Unit, Department of Research, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy. claudia.chiodoni@istitutotumori.mi.it.

Maria Teresa Di Martino (MT)

Department of Experimental and Clinical Medicine, University of Catanzaro "Magna Graecia", Catanzaro, Italy.

Francesca Zazzeroni (F)

Department of Biotechnological and Applied Clinical Sciences, University of L'Aquila, L'Aquila, Italy.

Michele Caraglia (M)

Department of Biochemistry, Biophysics and General Pathology, University of Campania "L. Vanvitelli", Naples, Italy.

Massimo Donadelli (M)

Department of Neurosciences, Biomedicine and Movement Sciences, Section of Biochemistry, University of Verona, Verona, Italy.

Stefania Meschini (S)

National Center for Drug Research and Evaluation, National Institute of Health, Rome, Italy.

Carlo Leonetti (C)

UOSD SAFU, IRCCS-Regina Elena National Cancer Institute, Rome, Italy.

Katia Scotlandi (K)

Experimental Oncology Lab, CRS Development of Biomolecular Therapies, Orthopaedic Rizzoli Institute, Bologna, Italy. katia.scotlandi@ior.it.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH